Company profile
Sibannac, Inc.
OTC: SNNC · Healthcare · Medical - Pharmaceuticals
#930 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ 18GM —SS 27
v0.1 · 25/100 weight · pillars only
↑ 3-yr revenue growth, growth stability · ↓ workforce scale, filing timeliness
Methodology →Revenue TTM
$5.5k
Rev growth YoY (TTM)
+61.1%
Net income (FY)
-$351.0k
Employees
1
as of 2026-08-27
Market cap
$154.4k
as of 2026-08-27
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$523.7k$523.7k2016
Net income-$351.0k-$351.0k2016
Operating income-$199.4k-$199.4k2016
Total assets$322.8k$322.8k2016
Liabilities$615.6k$615.6k2016
Equity-$292.8k-$292.8k2016
Revenue trend
FY2012 – FY2016 · USD
FY12
FY12
FY13
FY15
FY15
FY16
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Sibannac, Inc.’s revenue?
Sibannac, Inc. booked $523.7k in FY2016 revenue — among the slowest-growing Healthcare companies we track, at a -67.0% net margin.
Peers · Healthcare
Solana Company49DCardax, Inc.——Lipella Pharmaceuticals Inc.——Medivolve Inc.——DiaMedica Therapeutics Inc.35DZenith Capital Corp.——Neighbors
Maricopa →Key facts
CEODavid A. Mersky
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersPhoenix, AZ
ExchangeOTC: SNNC
Employees1
IPO date2014-02-10
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.